Definium Therapeutics, Inc. (DFTX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -227.54M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 154.65M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-227.54M | (m) | (m) | $154.65M | (m) | (m) |
| 2026-03-31 | $-193.37M | (m) | (m) | $135.79M | (m) | (m) |
| 2025-12-31 | $-166.31M | (m) | (m) | $117.67M | (m) | (m) |
| 2025-09-30 | $-151.19M | (m) | (m) | $105.90M | (m) | (m) |
| 2025-06-30 | $-130.32M | (m) | (m) | $92.11M | (m) | (m) |
| 2025-03-31 | $-113.87M | (m) | (m) | $76.95M | (m) | (m) |
| 2024-12-31 | $-103.92M | (m) | (m) | $65.30M | (m) | (m) |
| 2024-09-30 | $-93.66M | (m) | (m) | $55.08M | (m) | (m) |
| 2024-06-30 | $-90.48M | (m) | (m) | $51.10M | (m) | (m) |
| 2024-03-31 | $-95.21M | (m) | (m) | $51.23M | (m) | (m) |
| 2023-12-31 | $-93.87M | (m) | (m) | $52.12M | (m) | (m) |
| 2023-09-30 | $-85.56M | (m) | (m) | $49.41M | (m) | (m) |
| 2023-06-30 | $-80.93M | (m) | (m) | $43.98M | (m) | (m) |
| 2023-03-31 | $-68.69M | (m) | (m) | $38.53M | (m) | (m) |
| 2022-12-31 | $-66.33M | (m) | (m) | $36.17M | (m) | (m) |
| 2022-09-30 | $-69.99M | (m) | (m) | $38.22M | (m) | (m) |
| 2022-06-30 | $-70.23M | (m) | (m) | $39.47M | (m) | (m) |
| 2022-03-31 | $-98.51M | (m) | (m) | $38.22M | (m) | (m) |
| 2021-12-31 | $-93.85M | (m) | (m) | $34.79M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-33.03M | (m) | (m) | $18.63M | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |